Psomagen, Inc. engages in the provision of genomic, transcriptomic, and proteomic analysis to research programs and operations, serving academic, pharma, biotech, government, and industry. It develops technologies such as short and long-read next-generation sequencing (NGS), Sanger (CE) sequencing, microarray, single-cell omics, metagenomics and microbiome, spatial biology, bioinformatics, and biomarker discovery. The company was founded on December 2, 2004 and is headquartered in Rockville, MD.
Fundamental metrics to determine fair value of the stock
Company’s recent performance and margins
Dividend yield, history and sustainability
Financial position and solvency of the company